Zobrazeno 1 - 10
of 24
pro vyhledávání: '"rajanikanth vangipurapu"'
Publikováno v:
Skeletal Muscle, Vol 14, Iss 1, Pp 1-18 (2024)
Abstract Background Facioscapulohumeral muscular dystrophy (FSHD) is a common and progressive muscle wasting disease that is characterized by muscle weakness often first noticed in the face, the shoulder girdle and upper arms before progressing to th
Externí odkaz:
https://doaj.org/article/112632cc1416496c87ef5d0255b3353f
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Facioscapulohumeral muscular dystrophy (FSHD) is a degenerative muscle disease caused by loss of epigenetic silencing and ectopic reactivation of the embryonic double homeobox protein 4 gene (DUX4) in skeletal muscle. The p38 MAP kinase inhi
Externí odkaz:
https://doaj.org/article/b095dde51d5a40108b79744a15149e2f
Publikováno v:
In Cell Reports 2 January 2018 22(1):72-83
Publikováno v:
In Protein Expression and Purification May 2015 109:113-119
Autor:
Saïd M. Sebti, José Trevino, John Koomen, Eric A. Welsh, Mokenge Malafa, Jason B. Fleming, Patrick Underwood, Kazim Husain, Terence M. Williams, Bin Fang, Francisca Beato, Hua Yang, Rajanikanth Vangipurapu, Shengyan Xiang, Liwei Chen, Aslamuzzaman Kazi
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3c5c7bb40829ed9e2c0a6092ad296a
https://doi.org/10.1158/1078-0432.22480673.v1
https://doi.org/10.1158/1078-0432.22480673.v1
Autor:
Saïd M. Sebti, José Trevino, John Koomen, Eric A. Welsh, Mokenge Malafa, Jason B. Fleming, Patrick Underwood, Kazim Husain, Terence M. Williams, Bin Fang, Francisca Beato, Hua Yang, Rajanikanth Vangipurapu, Shengyan Xiang, Liwei Chen, Aslamuzzaman Kazi
Purpose:Among human cancers that harbor mutant (mt) KRas, some, but not all, are dependent on mt KRas. However, little is known about what drives KRas dependency.Experimental Design:Global phosphoproteomics, screening of a chemical library of FDA dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5522e5fa9b7383df56badf8e1b5b2172
https://doi.org/10.1158/1078-0432.c.6530501
https://doi.org/10.1158/1078-0432.c.6530501
Autor:
Saïd M. Sebti, José Trevino, John Koomen, Eric A. Welsh, Mokenge Malafa, Jason B. Fleming, Patrick Underwood, Kazim Husain, Terence M. Williams, Bin Fang, Francisca Beato, Hua Yang, Rajanikanth Vangipurapu, Shengyan Xiang, Liwei Chen, Aslamuzzaman Kazi
Supplementary Figures Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5d61663c85de4f79cf80423cc27a7c
https://doi.org/10.1158/1078-0432.22480658.v1
https://doi.org/10.1158/1078-0432.22480658.v1
Autor:
Quintana, Ariel, Rajanikanth, Vangipurapu, Farber-Katz, Suzette, Gudlur, Aparna, Zhang, Chen, Jing, Ji, Zhou, Yubin, Rao, Anjana, Hogan, Patrick G.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 2015 Dec . 112(51), E7083-E7092.
Externí odkaz:
https://www.jstor.org/stable/26466212
Autor:
Terence M. Williams, Shengyan Xiang, Francisca Beato, Hua Yang, Jose G. Trevino, Jason B. Fleming, Bin Fang, Said M. Sebti, Kazim Husain, Aslamuzzaman Kazi, Mokenge P. Malafa, Liwei Chen, rajanikanth vangipurapu, John M. Koomen, Eric A. Welsh, Patrick W. Underwood
Publikováno v:
Clin Cancer Res
Purpose: Among human cancers that harbor mutant (mt) KRas, some, but not all, are dependent on mt KRas. However, little is known about what drives KRas dependency. Experimental Design: Global phosphoproteomics, screening of a chemical library of FDA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c4aa6bdce35bb73eb6802d9949d267
https://doi.org/10.1158/1078-0432.ccr-20-4781
https://doi.org/10.1158/1078-0432.ccr-20-4781
Autor:
Perry Kennedy, Said M. Sebti, Karen C. Morrison, Paul J. Hergenrother, Liwei Chen, rajanikanth vangipurapu
Publikováno v:
Cancer Research. 78:1669-1669
Mutant KRas is a major driver of human cancer, yet currently no clinically approved therapies that directly target mutant KRas are available. In order to identify novel drugs that bind either mutant KRas or its effector Raf-1, we used alpha-screen an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6d9f5f52a6460dbe849b32c355e1808
https://doi.org/10.1158/1538-7445.am2018-1669
https://doi.org/10.1158/1538-7445.am2018-1669